<DOC>
	<DOCNO>NCT02066181</DOCNO>
	<brief_summary>This randomized phase III trial compare effect , good and/or bad , sorafenib tosylate treat patient desmoid tumor aggressive fibromatosis . Sorafenib tosylate may stop growth tumor cell block protein need cell growth .</brief_summary>
	<brief_title>Sorafenib Tosylate Treating Patients With Desmoid Tumors Aggressive Fibromatosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare progression-free survival ( PFS ) rate patient desmoid tumor ( DT ) /deep fibromatosis ( DF ) receive either sorafenib ( sorafenib tosylate ) placebo use double-blinded randomized phase III study . SECONDARY OBJECTIVES : I . To assess toxicity . II . To assess time surgical intervention . III . To assess tumor response rate survival . TERTIARY OBJECTIVES : I . To evaluate change magnetic resonance imaging ( MRI ) Tesla ( T ) 2 predict ( correlate ) biological effect tumor growth ( Response Evaluation Criteria Solid Tumors [ RECIST ] version [ v ] 1.1 ) , pain palliation . ( Correlative companion study ) II . The mechanism action sorafenib DT/DF remain unknown . In patient consent undergo paired tumor biopsy ( A091105-ST1 ) , treatment induce change quantify histology , gene expression profiling , proteomic change select interrogation key pathways western blot reverse transcription-polymerase chain reaction ( RT-PCR ) . ( Correlative companion study ) III . To collect archival tissue , baseline ( tumor , blood ) day 8 ( tumor , blood ) specimens basic science research ( A091105-ST1 ) . ( Correlative companion study ) IV . To assess patient-reported adverse event quality life ( QOL ) measure Patient-Reported Outcomes-Common Terminology Criteria Adverse Events ( PRO-CTCAE ) single-item overall Linear Analogue Self-Assessment ( LASA ) ( A091105-HO1 ) . ( Correlative companion study ) V. To assess pain palliation measure `` bad pain '' item Brief Pain Inventory Short Form ( A091105-HO1 ) . ( Correlative companion study ) OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive sorafenib tosylate orally ( PO ) daily ( QD ) day 1-28 . ARM II : Patients receive placebo PO QD day 1-28 . Patients may crossover Arm I upon disease progression . In arm , course repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow annually 3 year .</detailed_description>
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<mesh_term>Fibroma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients must confirmation DT/DF local pathologist prior registration Patients may treat locoregional therapy major surgery , radiation , radiofrequency ablation , cryosurgery provide complete least 4 week prior registration recover therapy related toxicity less CTCAE grade 2 Patients may treat cytotoxic , biologic ( antibody ) , immune experimental therapy , tyrosine kinase inhibitor , hormone inhibitor nonsteroidal antiinflammatory drug ( NSAIDs ) provide complete least 4 week prior registration ( 6 week mitomycin nitrosoureas ) recover therapy relate toxicity less CTCAE grade 2 Patients prior current treatment sorafenib exclude No concomitant treatment , therapeutic dos , anticoagulant warfarin warfarinrelated agent , heparin , thrombin Factor Xa inhibitor , antiplatelet agent ( e.g. , clopidogrel ) ; low dose aspirin ( = &lt; 81 mg/day ) , lowdose warfarin ( = &lt; 1 mg/day ) , prophylactic low molecular weight heparin ( LMWH ) permit ; please note drug strongly induce inhibit cytochrome P450 , family 3 , subfamily A , polypeptide 4 ( CYP3A4 ) associate risk torsades allow ; chronic concomitant treatment CYP3A4 inducer allow ( e.g. , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's wort ) ; part enrollment/informed consent procedure , patient counsel risk interaction agent , new medication need prescribe patient consider new overthecounter medicine herbal product ; follow drug strong inhibitor CYP3A4 allow treatment sorafenib : Boceprevir Indinavir Nelfinavir Lopinavir/ritonavir Saquinavir Telaprevir Ritonavir Clarithromycin Conivaptan Itraconazole Ketoconazole Mibefradil Nefazodone Posaconazole Voriconazole Telithromycin Drugs possible conditional risk torsades use caution know sorafenib could prolong QT interval Chronic daily NSAID use treatment control desmoid tumor allow , stop &gt; = 3 day prior registration ; NSAIDS allow use desmoid tumorrelated pain symptom unrelated desmoid disease ( eg . headache , arthritis ) Patients must measurable disease Patients meet one follow criterion eligible : Disease determine unresectable entail unacceptably morbid surgery base 1 follow characteristic : Multifocal disease Disease involvement inadequate plane : neurovascular bundle , bone , skin , viscera Large size relationship location OR multicompartment involvement Progression radiographic image ( 10 % increase size RECIST v1.1 within 6 month registration ) Patients symptomatic disease meet follow criterion Brief Pain Inventory ( BPI ) score great equal 3 AND one following : Inability control pain NSAIDs consider addition narcotic OR &gt; 30 % increase current use narcotic OR Addition new opioid narcotic Eastern Cooperative Oncology Group ( ECOG ) performance status = &lt; 2 Patients pregnant nursing eligible No patient history cardiac disease : congestive heart failure &gt; class II New York Heart Association ( NYHA ) ; active coronary artery disease ( CAD ) ( myocardial infarction unstable angina within 6 month prior study entry ) No patient inadequately control hypertension ( define blood pressure &gt; = 150 mmHg systolic and/or &gt; = 90 mmHg diastolic ) , prior history hypertensive crisis hypertensive encephalopathy No patient clinically significant gastrointestinal ( GI ) bleed bleed diathesis within 30 day prior registration Absolute neutrophil count &gt; = 1,500/mm^3 Hemoglobin &gt; = 8 g/dl Platelets &gt; = 75,000/mm^3 Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) /serum glutamate pyruvate transaminase ( SGPT ) ( aspartate aminotransferase [ ALT ] ) = &lt; 1.5 x ULN Calculated creatinine clearance &gt; = 50 mL/min use CockcroftGault equation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>